resDetect? Human FGF2 ELISA Kit (Residue Testing)

產(chǎn)品概述(Product Overview)
resDetect? Human FGF2 ELISA Kit (Residue Testing) is based on the ELISA sandwich method and is used to detect and quantitatively determine GMP human FGF2 residues in cell culture supernatants, serum, and plasma. The kit contains GMP human FGF2 (ACROBiosystems, cat# GMP-FGCH17) to ensure accurate assay results and is designed to provide a reliable solution for CAR-T product quality assessment during drug development and CMC quality control stages. It can also be used as a universal detection tool for the quantitative determination of human FGF2
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
存儲(chǔ)(Storage)

背景(Background):FGF2
FGF basic (also known as FGF2 and HBGF-2) is an 18-34 kDa, heparin-binding member of the FGF superfamily of molecules. Superfamily members are characterized by the presence of a centrally placed beta -trefoil structure. FGF acidic (FGF-1) and FGF basic (FGF2) were the first two identified FGFs, and the designations acidic and basic refer to their relative isoelectric points. Human FGF basic is 288 amino acids (aa) in length. There are multiple start sites, four of which utilize atypical CUG codons, and one that initiates at an AUG start site. The four CUG start sites generate high molecular weight (HMW) FGF basic. There is a 34 kDa, 288 aa form, a 24 kDa, 210 aa form, a 22.5 kDa, 201 aa form, and a 22 kDa, 196 aa form. All are retained intracellularly, undergo extensive methylation, and possess one or more nuclear localization signals (NLS). The AUG initiating form is 18 kDa and 155 aa in length. There is no signal sequence (ss). It is, however, secreted directly through the plasma membrane via a mechanism that appears to be dependent upon tertiary structure. In place of a ss, there is purportedly a 9 aa N-terminal prosegment that precedes a 146 aa mature segment. Early isolations of 18 kDa bovine FGF basic yielded 146 aa molecules, an effect attributed to the presence of acid proteases. The molecule contains a heparin-binding site (aa residues 128-144), and undergoes phosphorylation at Ser117. There is also an ill-defined C-terminal NLS that may be more “functional” (or 3-dimensional) than structural. Human 146 aa FGF basic is 97% aa identical to mouse FGF basic.
關(guān)鍵字: FGF2;FGF2試劑盒;FGF2 ELISA試劑盒;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。